177 Lu has sprung as a promising radionuclide for targeted therapy. The low soft tissue penetration of its β - emission results in very efficient energy deposition in small-size tumours. Because of this, 177 Lu is used in the treatment of neuroendocrine tumours and is also clinically approved for prostate cancer therapy. In this work, we report a separation method that achieves the challenging separation of the physically and chemically identical nuclear isomers, 177m Lu and 177 Lu. The separation method combines the nuclear after-effects of the nuclear decay, the use of a very stable chemical complex and a chromatographic separation. Based on this separation concept, a new type of radionuclide generator has been devised, in which the parent and the daughter radionuclides are the same elements. The 177m Lu/ 177 Lu radionuclide generator provides a new production route for the therapeutic radionuclide 177 Lu and can bring significant growth in the research and development of 177 Lu based pharmaceuticals.
ASJC Scopus subject areas